Find an Article

Filter articles

Applied Filters

Showing 241 to 250 of 288 results

The post-Medeva SPC saga: what about biologicals?

EU20-06-2014Jaap Mannaerts

For those involved in the development of biological drugs, the prospects of getting what would seem to be a ‘fair reward’ may not have improved much, says Jaap Mannaerts.

Tough times continue for stem cell patents

EU20-06-2014Franz-Josef Zimmer and Markus Grammel

The exclusion from patentability of certain cells derived from human embryos is a reflection of the EPO’s increasingly restrictive stance, say Franz-Josef Zimmer and Markus Grammel.

Indian patent law: a new direction

India20-06-2014Archana Shanker

Recent decisions suggest that the Indian system seems to be changing direction towards developing sound patent law jurisprudence, says Archana Shanker.

Subject matter eligibility: interpreting the USPTO guidelines

US30-05-2014Courtenay C. Brinckerhoff

The new examination guidelines do not carry the weight of law, and it is not likely that their more extreme aspects will withstand judicial scrutiny, but practitioners need to keep tabs on court decisions, says Courtenay C. Brinckerhoff.

Protecting biomarkers and personalised/stratified medicine

EU, US30-04-2014Stephanie Pilkington

With careful patent drafting and prosecution, it is possible to capture significant IP value in the clinically—and commercially—important area of biomarkers, says Stephanie Pilkington of Potter Clarkson.

Combating cancer: Apexigen and rabbit antibodies


Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies.

More bang for your buck: second medical use and the EPC 2000

EU19-02-2014Caroline Pallard

Second and further medical use claims provide companies and patent lawyers with interesting opportunities, as Caroline Pallard explains.

Aiming high: Canadian biotech


In a global league, Canada’s biotech industry would be respectably mid table. LSIPR talks to Andrew Casey, president of industry association BIOTECanada, about how the organisation is trying to take it to the next level.

Cellular Dynamics: cells to order


Stem cells are seen by many as the great hope for medical research in the years to come. LSIPR spoke to Nicholas Seay, chief technology officer at Cellular Dynamics, about the importance of IP in this field.

Patenting diagnostic methods post-Myriad

US03-12-2013Antoinette Konski

The first US court decision applying the Myriad decision has landed, and it makes for interesting reading, as Antoinette Konski reports.

Showing 241 to 250 of 288 results